Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
? CORONAVIRUS http://www.biostarpharmaceuticals.com/
PARTNERS/ SUBSIDIARIES
Shaanxi Aoxing Pharm
Shaanxi University
NVCC BCRX GILD INO MRNA NVAX
toto - ofc not, but the delisting timing was too much of a high risk for us as mentioned in our blog's comments.
But well, we got a good trade from the 7/25 dip :-/
Just checking back this old chestnut, but you get no news at all.
This new Director buys 16% of the co. for over 600k in July and says she has a new business plan for the company. Well its very secretive whatever she is planning.
Finesand.......did you die along with the company, you were posting everyday and then you disappear. It appears that something is going on there are no shares to buy, and there is no news of the company closing down.
The Company has closed down, I dont know why its trading on OTC. It makes no sense.
So are these guys coming back or staying pink forver?> Even their website is down. Cant file fins nor pay web fees?
Potential Suspension on Friday if Nasdaq doesn't give the stay until hearing decision or even Delisting if Nasdaq doesn't like the new presented material.
We have written that in our blog regarding this event.
This was a public service (o8>
PS: We would give our left arm to know the decision upfront (o8>
But then, even the positive stay until hearing decision is not yet the hail mary. Also, we really don't know anymore about the asset value after Liao's cheap purchase. So everything can go here. Just watching the drama.
smart- it is a long & complicated story here.
On first sight you are correct and the overdone pop
after the overdone plunge is typical for this low float stock.
Statistically, I have checked a few, a 29% plunge on the same reasons (delist determination based on late filing) gets recovered on the hearing 15d extension.
Here it overshoot 'a little bit' :)
Within next 15d we will learn whether company gets delisted or they can convince NASDAQ they have or can cure all the issues mentioned and stay.
See https://finesand.wordpress.com/2018/07/25/biostar-pharmaceuticals-bspms-nasdaq-delisting-notification/
and in general for the whole story https://finesand.wordpress.com/tag/bspm/
* * $BSPM Video Chart 07-27-18 * *
Link to Video - click here to watch the technical chart video
manipulated GAP & TRAP
happens often with listed low float stocks
that are manipulated like BSPM
goes up on delisting notice
SMH
sucks people in to chase, then drops the hammer on them
* * $BSPM Video Chart 07-26-18 * *
Link to Video - click here to watch the technical chart video
Delisting Determination
Times just went 'a little more' rough with this tiny stock ..
Whole coverage of impact and background ..
Appeal/Hearing next ..
A little query shows that a delisting determination lead delisting threat due to late 10-k/q filings usually cause initial dips around 29%, but then fully recover relatively quickly since the appeal/hearing has been requested.
Not a trading advice.
https://finesand.wordpress.com/2018/07/25/biostar-pharmaceuticals-bspms-nasdaq-delisting-notification/
Pivot Value Play - Compilation (update)
- On REGSHO since 7/17
- IB has no more shorts available on 7/18
- Main article Pivot Value Play (incl. full timeline) and detailed Earnings Projection
- Liao Huiping BOD took ownership from CEO + Company Liens/Debts Cleaned
- Liao Huiping is also a 2nd leader of parent YKP
- De-risked Delinquency Late Filer Status
-- 31 days post NASDAQ deadline
-- Compliance plan to file late accepted
-- New Auditor Centurion is on this for 5 month already
- Cured Going Concern Note of Shaanxi Aoxing’s GMP License Loss
- Sales of new produced drugs from Shanxi Aoxin
- Closing of Intended Acquisitions
- Sale of Shaanxi Weinan Huaren Pharmaceuticals
- Recent Timeline
- Historical Revenue and Today’s Value
(All BSPM Posts)
Look at Yue Kai Peng Group here, the master.
Liao Huiping News were awesome already, but she connected us to the 6B Yuan Yue Kai Peng Group.
No NASDAQ delisting for sure, they have bigger plans with BSPM staying on NASDAQ as stated on their own strategic development website.
https://finesand.wordpress.com/2018/07/05/biostar-pharmaceuticals-bspms-ownership-more-to-come/
Re: Ownership Reorg – A Clean Restart
Fixed and aligned new owner name to Liao Huiping (Mandarin translation, surname Liao first). Few details were edited and added.
All we can say is: Go Liao Huiping, make BSPM functioning again
- CEO Wang’s Debt payed off, Company’s assets freed, no liens nor litigation
- Liao Huiping takes controlling stake into Company from Mr Wang
- Liao Huiping seeks to remove Mr Wang from BOD Chairman position
- Liao Huiping seeks to reshape overall BOD, essentially taking full control
- Liao Huiping seeks to implement new business plans
https://finesand.wordpress.com/2018/07/02/biostar-pharmaceuticals-bspms-ownership-reorg-a-clean-restart/
+++
Ownership Reorg – A Clean Restart
https://finesand.wordpress.com/2018/07/02/biostar-pharmaceuticals-bspms-ownership-reorg-a-clean-restart/
When you think time gets boring until company files the late 10-K, think again. Company’s BOD and influential successful businesswoman Waiping Liu, also known as Huiping Liu or Huiping Liao under Chinese pronunciation, bought a 16.2% controlling stake of the company. She filed her Schedule 13D on 2018-07-02 at 17:00:22. In summary
- CEO Wang’s Debt payed off, Company’s assets freed, no liens nor litigation
- Huiping Liu takes controlling stake into Company from Mr Wang
- Huiping Liu seeks to remove Mr Wang from BOD Chairman position
- Huiping Liu seeks to reshape overall BOD, essentially taking full control
- Huiping Liu seeks to implement new business plans
two blogs were added, detailing the base article
BSPM's Earnings Projection https://finesand.wordpress.com/biostar-pharmaceuticals-bspm-earnings-projection/
Detailing the $6 - $12 PTs.
+++
BSPM's 2017 and 2018's Late Filing https://finesand.wordpress.com/biostar-pharmaceuticals-bspms-2017-and-2018s-late-filing/
My personal tagline here Golden Silence until 10-K filed by now, beyond delisting timeframe
Biostar Pharmaceuticals (BSPM) Pivot Value Play (update)
- De-risked Delinquency Status
- Cured Going Concern Note of Shaanxi Aoxing’s GMP License Loss
- Sales of new produced drugs from Shanxi Aoxin
- Closing of Intended Acquisitions
- Sale of Shaanxi Weinan Huaren Pharmaceuticals
- Recent Timeline
- Historical Revenue and Today’s Value
https://finesand.wordpress.com/biostar-pharmaceuticalss-bspm-pivot-value-play/
BSPM’s Delinquency Status
Read my friend's assessment about BSPM's delinquency status https://finesand.wordpress.com/biostar-pharmaceuticals-bspm-delinquency/
Excerpt here:
+++
Now I called NASDAQ today on 2018-06-28 12pm EST at +1 301 978 8008 and they told me they could not give me any specific information regarding any company’s filing status and I would need to have to wait until news are being presented. Persistent as I am, I asked her about their general procedure in these cases:
- What happens if NASDAQ accepts the plan after the 60 days (here after 6/18)?
- What happens if NASDAQ rejects the plan after the 60 days (here after 6/18)?
Here answer (by memory):
- If we accept the plan, Company has not to PR anything. They only need to PR and file the deficiency letter. We also do not PR or file anything in this case.
- If we deny the plan, in general we will send a delisting notice out within 5 days.
....
Today is the 8th business day or 10th calendar day after the 60 day deadline on 6/18.
One may want to adjust their risk / reward assessment the longer we get away from 6/18. IMHO, the delisting risk is already gone by now, at least this is my opinion.
+++
Biostar Pharmaceuticals (BSPM) Pivot Value Play
Complete story & coverage including latest events of sale of Shaanxi Weinan Huaren (As claimed by purchasing company Guangdong Jianquan Pharmaceutical)
https://finesand.wordpress.com/biostar-pharmaceuticalss-bspm-pivot-value-play/
Interesting Findings re Shanxi Weinan Huaren Pharmaceuticals
Shanxi Weinan Huaren Pharmaceuticals has been claimed to be bought by Guang Dong Jian Quan in January 2017, see http://www.healthr.com/company/50FSo/
Now that is quite interesting (o8>
Weinan was bought in 2011 for roughly 61M RMB or $9.6M
and is now claimed to have asset value of around
"Shaanxi Weinan Huaren Pharmaceutical Co., Ltd. covers an area of 50 acres, a registered capital of 80 million yuan"
It would explain how company was able to renovate Shanxi Aoxing, get the GMP license back in Dec'17 and already kicked of production and sales.
Since the letter was very unlikely to happen while certain assets were claimed by creditors!
Conclusion based on previously posted proof that sales of new production occurs: They are clean by now.
So .. again, waiting for the audited 10-K.
GL
PS: Not a pump, but speculation based on this DD
Updated spreadsheet in Intro, etc
It is t is the bigger parent Shaanxi Aoxing
not the smaller Shaanxi Weinan regaining its GMP license.
Shaanxi Weinan actually lost its GMP license in 2017.
Let's see what Mr CEO Wang has achieved within the last months, actually two quarters. As posted earlier here, production has been kicked off and we have found evidence that new production is already being sold.
Assuming he does not let go his stock from Nasdaq and is simply just late again with financial filings like in 2017, we shall soon learn about the details within the next 14 days maximum.
In case production and sales is being ramped up properly again, we should expect a price correction towards the $6/sh refundable deposit value at least.
Highly volatile stock .. otherwise.
Historical Evaluation on using 12month MA and 10-K data + Projections + Deposit Details
Annual YoY Fundamentals using 12 month MA for lower stock price
seriously, we believe they just file late as usual of course
and release news thereafter.
sadly stock is traded so thinly, hard to accumulate (o8>
Over 6/18 financial filing + listing deadline again
Rolling the dice like last year again?
Nasdaq closing both eyes again?
Maybe running bets on the side?
1) Filing within 5, 10 or 15 days - NASDAQ is OK
2) NASDAQ shuts them down
Follow-on bets
1.1) Production and sales news
2.1) China listing (intentional)
This stock never gets boring, within its own class (o8>
We are most curious about the financials of course,
since productions seems to have been started already.
They just don't tell .. must be a special policy of them (o8>
tick tock: 6/18 + 15 days?
Last year BSPM was also delinquent on two financial reports, but 'just' quarterlies - now one audited annual.
Last year they had time until around end of October and started filing their 10-Q 11/15 .. so 15 days extra late (o8>
Only thereafter they showed 'new' development, which of course already happened.
Assuming Nasdaq will be just patient and nice again, maybe a similar 'slide until filed' play will continue.
Let's see how they play it this year ..
One thing for sure, after 10-K and 1Q18 has been filed, watch out for the cash position, refundable deposits and OS of course.
Status update?
Company is now late on its 1Q18 10-Q as well, NT 10-Q filed.
We expect company needs to file the audited 4Q17 10-K before the 1Q18 10-Q first, so that may take a little while since they changed their auditor recently.
They have about 30 more days of the 60 days grace perdiod, last time they exceeded the initial 60 days and all was OK.
While they are a late filer as of now (10-K), they cannot issue new shares. We are unsure whether they can release material positive news until they are current. This is not a written rule, but probably not seen positive.
.. just the usual waiting
oh, this truly has the potential
of going and staying even higher above $4 - see our previous DD.
NAV is $8 - $12 per share alone and production comeback would allow great stock support on high margins.
But yes, its a ride and all this might need to be officially disclosed by company etc.
Whichever higher bottom will be found next week > $2.20, subsequent news will support the followup gains as long they don't dilute far below their high NAV and are not too slow in picking up sales again.
I agree that this is coming back to the $2.50 range without news Monday. This hit the scanners on Friday and the day traders pounced. I got in at 2.04 and out at 3.35. Looking to do the same again very soon. Next target for me is in at 2.50 and out at 4.
Nice Pre-Official Reaction Today
Meaning stock moved either on a low float P&D or reflecting our DD regarding the production & sales artifacts.
We believe 8dema around $2.40 will hold on a slide until official news, which can be hard to time.
If this was just a premature low-float P&D it surely will come back, maybe even to $2.20'ish - if holders don't believe the DD or are still scared about the late 10-K.
We are not scared, however - we surely also traded the top above $3.
01 hinted to the January '18 trade before the GMP license PR and even thereafter, coming all the way back down before rising again. Surely today also acted on lower volume.
No real crystal-ball here, but we believe when company releases the production & sales news it will properly recover back to its refundable asset value at least. This especially if 1Q18 or 10-K (whichever comes first - hint) demonstrates stability.
Notice previous post regarding growth and revenue numbers while producing.
Good luck, this stock is heavily volatile.
* * $BSPM Video Chart 05-04-18 * *
Link to Video - click here to watch the technical chart video
And more just below
same site's shop finder shows not only one pharmacy
http://yp.120ask.com/buy/119232.html
We are looking forward to the late and lagging PR (as usual)
and 1Q18. May 4Q17 10-K follow right afterwards (o8>
valid for 24 month
Indicating that current products on sale with an expiration date of end of 2019 were produced quite recently (o8>
See http://yp.120ask.com/manual/119232.html
Translated parts:
New Product on Sale in Shaanxi Province
Forgot to post pictures ..
Expiration date end of 2019 with a 24 month shelf life